Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments

Cancer Immunity

Volumn 1, Issue , 2001, Pages 1-13

  Robert, Bruno ^a   Guillaume, Philippe ^b   Luescher, Immanuel ^c   Doucey, Marie Agnès ^c   Cerottini, Jean Charles ^c   Romero, Pedro ^b   Mach, Jean Pierre ^a,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

Cultured tumor cells; Cytotoxic T lymphocytes; Fab immunoglobulins; Immunoconjugates; Immunotherapy; MHC class I; Tumor antibodies

Indexed keywords

HLA A2 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; OLIGOMERIZATION; PROTEIN EXPRESSION; TUMOR IMMUNITY;

EID: 3142582516     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65. (PMID: 8011285)
2. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-300. (PMID: 10570323)
3. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-203. (PMID: 11027314)
4. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-94. (PMID: 7576053)
5. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today 1998; 19: 539-42. (PMID: 9864942)
6. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160: 1750-8. (PMID: 9469433)
7. Mach JP. Monoclonal antibodies. In: Peckham M, Pinedo H, Veronesi U, editors. Oxford Textbook of Oncology, Vol. 1. Oxford: Oxford University Press; 1995. p. 81-103.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48. (PMID: 10561337)
9. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33. (PMID: 9704735)
10. Robert B, Guillaume P, Luescher I, Romero P, Mach JP. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 2000; 30: 3165-3170. (PMID: 11093131)
11. Ogg GS, Dunbar PR, Cerundolo V, McMichael AJ, Lemoine NR, Savage P. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer 2000; 82: 1058-62. (PMID: 10737389)
12. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6. (PMID: 8810254)
13. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188: 1641-50. (PMID: 9802976)
14. Delaloye B, Bischof-Delaloye A, Buchegger F, von Fliedner V, Grob JP, Volant JC, Pettavel J, Mach JP. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986; 77: 301-11. (PMID: 3484753)
15. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A 1992; 89: 3429-33. (PMID: 1565634)
16. Buchegger F, Haskell CM, Schreyer M, Scazziga BR, Randin S, Carrel S, Mach JP. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983; 158: 413-27. (PMID: 6886623)
17. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-9. (PMID: 1350088)
18. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45. (PMID: 7506951)
19. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255-63. (PMID: 8102322)
20. Valitutti S, Dessing M, Aktories K, Gallati H, Lanzavecchia A. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med 1995; 181: 577-84. (PMID: 7836913)
21. Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A 1991; 88: 9287-91. (PMID: 1924393)
22. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 1997; 15: 1994-2007. (PMID: 9164211)
23. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999; 11: 570-8. (PMID: 10508704)
24. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628-31. (PMID: 2859527)
25. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti- target cell antibody. Nature 1985; 316: 354-6. (PMID: 3160953)
26. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 1991; 48: 227-33. (PMID: 1826900)
27. Luescher IF, Vivier E, Layer A, Mahiou J, Godeau F, Malissen B, Romero P. CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature 1995; 373: 353-6. (PMID: 7830771)
28. Wang B, Maile R, Greenwood R, Collins EJ, Frelinger JA. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J Immunol 2000; 164: 1216-22. (PMID: 10640733)
29. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med 2000; 191: 335-46. (PMID: 10637277)
30. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dorken B, Moldenhauer G. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 1988; 167: 345-52. (PMID: 2450158)
31. Yu Z, Healy F, Valmori D, Escobar P, Corradin G, Mach JP. Peptide-antibody conjugates for tumour therapy: a MHC-class-II- restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int J Cancer 1994; 56: 244-8. (PMID: 7906251)
32. Eberl G, Jiang S, Yu Z, Schneider P, Corradin G, Mach, JP. An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells. Clin Exp Immunol 1998; 114: 173-8. (PMID: 9822273)
33. Walter JB, Brander C, Mammen M, Garboczi DN, Kalams SA, Whitesides GM, Walker BD, Eisen HN. Stimulation of human cytotoxic T cells with HIV-1-derived peptides presented by recombinant HLA-A2 peptide complexes. Int Immunol 1997; 9: 451-9. (PMID: 9088983)
34. Valmori D, Fonteneau JF, Valitutti S, Gervois N, Dunbar R, Lienard D, Rimoldi D, Cerundolo V, Jotereau F, Cerottini JC, Speiser DE, Romero P. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 1999; 11: 1971-1980. (PMID: 10590263)
35. Ostankovitch M, Guichard G, Connan F, Muller S, Chaboissier A, Hoebeke J, Choppin J, Briand JP, Guillet JG. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J Immunol 1998; 161: 200-8. (PMID: 9647225)
36. Lone YC, Motta I, Mottez E, Guilloux Y, Lim A, Demay F, Levraud JP, Kourilsky P, Abastado JP. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. J Immunother 1998; 21: 283-94. (PMID: 9672850)
37. Le Doussal J, Piqueras B, Dogan I, Debre P, Gorochov G. Phage display of peptide/major histocompatibility complex. J Immunol Methods 2000; 241: 147-58. (PMID: 10915857)
38. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-68. (PMID: 9763615)
39. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208. (PMID: 9047241)
40. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 1998; 77: 538-42. (PMID: 9679755)
41. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85. (PMID: 10371507)
42. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190: 705-15. (PMID: 10477554)
43. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94: 1914-8. (PMID: 9050879)
44. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12: 1561-71. (PMID: 8040668)
45. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21: 403-10. (PMID: 10916144)
46. Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201- associated tyrosinase peptide 368-376. Cancer Res 1999; 59: 4050-5. (PMID: 10463606)
47. Robert B, Mach JP, Mani JC, Ychou M, Folli S, Artus JC, Pelegrin A. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res 1996; 56: 4758-65. (PMID: 8840995)